Latest Menorrhagia Stories
Scientists described yesterday the discovery of a new drug, which is currently in Phase II clinical trials, designed to specifically target the root cause of painful menstrual cramps, not just the symptoms.
PEORIA, Ariz., Feb.
SALT LAKE CITY, Jan.
AUSTIN, Texas, Jan.
BEDFORD, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Hologic, Inc.
NEWPORT, Ky., Nov.
SILVER SPRING, Md., Nov. 13 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
SOUTHAMPTON, England, October 6 /PRNewswire/ -- Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials.
WAYNE, N.J., Oct. 1 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc., announced today that the U.S.
SILVER SPRING, Md., Oct. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention.